Pharmacy Learning Network

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for sensipar (cinacalcet) tablets, 30 mg. The affected batch has been identified as Lot 1156858 (expires December 2027), affecting 9565 bottles.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for lacosamide tablets, USP, 100 mg. The affected batches have been identified as Lots A253999 and A254000 (expiration September 2027), affecting 31 392 bottles.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

AMP_PAGE_VIEWPending Maximum Storage Duration: SessionType: HTML Local Storage AMP_remote_config_090786228dPending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_090786228d_1780812854728Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_SR_START_090786228d_1780812929532Pending Maximum Storage Duration: PersistentType: HTML Local Storage AMP_URL_INFOPending Maximum Storage Duration: SessionType: HTML Local Storage EXP_090786228dPending Maximum...

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class II recall for chlorthalidone tablets, USP, 25 mg. The affected batch has been identified as Lots RISA24001 and RISB24002 (expiration April 2027), affecting 11 460 bottles. The recall was initiated by Inventia Healthcare Limited due to failed dissolution specifications, a quality issue that may cause temporary or medically reversible adverse health consequences.

Key Takeaways: The US Food and Drug Administration (FDA) has issued a voluntary Class III recall for Focalin XR (dexmethylphenidate HCl), 5 mg. The affected batch has been identified as Lot VA0099422 (expires June 2028), affecting 7803 bottles. The recall was initiated by Sandoz Inc due to incorrect labeling, a quality issue that is not likely to cause adverse health consequences. Dexmethylphenidate is used to treat attention deficit hyperactivity disorder (ADHD).

Key Takeaways The Pharmaceutical Care Management Association (PCMA) has filed a federal lawsuit against Illinois challenging portions of the state’s Prescription Drug Affordability Act (PDAA), arguing that key pharmacy benefit manager (PBM) transparency and network-design provisions are preempted by the Employee Retirement Income Security Act (ERISA).

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.